IL2 and metastatic melanoma: A phase I study for the combination of the IL-2 immunocytokine and the chemotherapeutic agent dacarbazine in metastatic melanoma exhibited low rates of severe toxicity, mainly grade 4 leukopenia/neutropenia and grade 3 hypotension.